Spyre TherapeuticsFRA:3920 +2.99%26 EV-to-FCF is -43.45 as of Jul. 11, 2026. GuruFocus rates FRA:3920 with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 330 Biotechnology companies, Spyre Therapeutics ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Spyre Therapeutics's Enterprise Value is €6,939.07 Mil.
Spyre Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-159.69 Mil. Therefore, Spyre Therapeutics's EV-to-FCF for today is -43.45.
The historical rank and industry rank for Spyre Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:3920'
s EV-to-FCF Range Over the Past 10 Years
Min: -42.57 Med: -2.5 Max: 2.79
Current: -42.57
During the past 13 years, the highest EV-to-FCF of Spyre Therapeutics was 2.79. The lowest was -42.57. And the median was -2.50.
FRA:3920's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs FRA:3920: -42.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Spyre Therapeutics's PE Ratio (TTM) for today is calculated as:
Spyre Therapeutics's share price for today is €86.00.
Spyre Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.919.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Spyre Therapeutics EV-to-FCF Related Terms
Spyre Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Spyre Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3920 vs MIRM, RYTM, PTGX: EV-to-FCF Comparison
For the Biotechnology subindustry, Spyre Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's EV-to-FCF falls into.
Spyre Therapeutics's current Enterprise Value is €6,939.07 Mil.
Spyre Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-159.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (FRA:3920) has a EV-to-FCF of -43.45 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry.
Is Spyre Therapeutics' EV-to-FCF too high?
Spyre Therapeutics' current EV-to-FCF is -43.45. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' EV-to-FCF compare to MIRM and RYTM?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 330 companies for EV-to-FCF. This places Spyre Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current EV-to-FCF is -43.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current EV-to-FCF of -43.45. The current EV-to-FCF is -43.45. Spyre Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current EV-to-FCF is -43.45 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score
Get the complete analysis for FRA:3920
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3920 has been successfully added to your 
